| Birth Place | Delhi, India, India |
Malvinder and Shivinder Singh are prominent figures in the healthcare industry in India. As successful businessmen and entrepreneurs, their net worth is estimated to be an impressive $1.38 billion by the year 2024. Known for their investments and ventures in the healthcare sector, the Singh brothers have played a significant role in transforming the landscape of healthcare services in India. Their entrepreneurial journey has seen the establishment of several healthcare companies, bringing cutting-edge technology and innovative solutions to the Indian healthcare system. With their substantial net worth, the Singh brothers continue to make valuable contributions to the growth and development of healthcare in India.
Malvinder Mohan Singh is one of the son of Dr. Parvinder Singh and the grandson of Bhai Mohan Singh, the founder of Ranbaxy. He and his brother Shivinder Singh, who in 1999 upon the death of their Father inherited their family's 33.5% stake in Ranbaxy, are among the twenty richest Indians.
Malvinder Singh's tenure as CEO of Ranbaxy starting in 2006 is controversial. Corporate culture of fraud continued unchecked under his tenure. In November 2006, Malvinder Singh led a delegation to FDA headquarters to try to reverse the decision to accept new drug applications from Ranbaxy. This attempt failed as FDA asked Ranbaxy to turn over audits done by its outside consultant, Parexel, which the company was claiming were confidential. The meeting ended in a standoff. Soon thereafter Mr. Singh decided to cash in. On 11 June 2008, Singh stunned the Indian Business world by announcing that he and his brother were selling their 34% stake in Ranbaxy to the Japanese drugmaker Daiichi Sankyo for $2 billion.
